From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
It is crucial that we instrument the entire patient journey so we can understand what, if any, obstacles they’re encountering.”
Vice President | Market Access
Use data to identify patient journey obstacles and develop patient initiation and patient adherence solutions.
With accurate, real-time patient data, manufacturers better understand the barriers affecting patient initiation.
Industry research shows that 30% to 50% of scripts never get filled. Manufacturers can gain insights into payer, channel, and provider-related obstacles impacting the pharma patient journey by properly leveraging patient status data.
Even once the patient initiates therapy, adherence is hardly guaranteed. Ongoing payer issues, out-of-pocket costs, and side effects are a few of the factors that complicate the patient journey.
In fact, the National Institute of Health data shows that adherence rates for most medications for chronic conditions such as diabetes and hypertension usually fall in the 50% to 60% range, even with patients who have good insurance and drug benefits. To combat this, pharmaceutical manufacturers often throw money into an array of patient services programs, but without accurate patient status and dispensing data, these programs can be a huge investment with little return.
Pharmaceutical manufacturers need access to reliable, consistent, and timely patient data in order to make business decisions that affect their bottom line. Whether you’re an existing manufacturer trying to identify breakdowns in patient adherence or you’re an emerging manufacturer trying to get a handle on co-pay program costs, IntegriChain can turn mountains of patient access data into actionable insights for your pharma market access teams.
Every specialty pharmaceutical manufacturer needs answers to a common set of critical business questions around patient initiation and patient adherence:
Unfortunately, manufacturers often realize each specialty pharmacy has its own ways of calculating metrics and statuses. They also frequently uncover:
These issues often prevent manufacturers from getting a clear, consistent line of sight into the pharma patient journey, including medication access and adherence. IntegriChain understands how to amplify the manufacturer-specialty pharmacy relationship and make the patient status the central point of efficient, data-driven collaboration.
Improve your pharma patient access process
Learn how IntegriChain applied machine learning and data science to help a major pharmaceutical manufacturer gain deep insight into the timing, cost, and effectiveness of patient intervention programs.
Read the Case Study
Market Access leaders from DBV Technologies, Sesen Bio, and Karyopharm Therapeutics discuss strategies to overcome obstacles to patient initiation and adherence.
Read more